Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ABMD's Cash to Debt is ranked higher than
86% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.15 vs. ABMD: No Debt )
ABMD' s 10-Year Cash to Debt Range
Min: 31.75   Max: No Debt
Current: No Debt

Equity to Asset 0.81
ABMD's Equity to Asset is ranked higher than
84% of the 445 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ABMD: 0.81 )
ABMD' s 10-Year Equity to Asset Range
Min: 0.72   Max: 0.94
Current: 0.81

0.72
0.94
Interest Coverage No Debt
ABMD's Interest Coverage is ranked higher than
79% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 231.38 vs. ABMD: No Debt )
ABMD' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 8
Z-Score: 38.92
M-Score: -2.63
WACC vs ROIC
13.04%
21.83%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 9.37
ABMD's Operating margin (%) is ranked higher than
82% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 6.13 vs. ABMD: 9.37 )
ABMD' s 10-Year Operating margin (%) Range
Min: -111.48   Max: 10.46
Current: 9.37

-111.48
10.46
Net-margin (%) 8.65
ABMD's Net-margin (%) is ranked higher than
83% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.35 vs. ABMD: 8.65 )
ABMD' s 10-Year Net-margin (%) Range
Min: -84.54   Max: 9.5
Current: 8.65

-84.54
9.5
ROE (%) 10.59
ABMD's ROE (%) is ranked higher than
84% of the 446 Companies
in the Global Medical Devices industry.

( Industry Median: 5.76 vs. ABMD: 10.59 )
ABMD' s 10-Year ROE (%) Range
Min: -46.87   Max: 11.4
Current: 10.59

-46.87
11.4
ROA (%) 8.69
ABMD's ROA (%) is ranked higher than
89% of the 477 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. ABMD: 8.69 )
ABMD' s 10-Year ROA (%) Range
Min: -42.19   Max: 9.27
Current: 8.69

-42.19
9.27
ROC (Joel Greenblatt) (%) 100.17
ABMD's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 476 Companies
in the Global Medical Devices industry.

( Industry Median: 9.33 vs. ABMD: 100.17 )
ABMD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -294.77   Max: 90.23
Current: 100.17

-294.77
90.23
Revenue Growth (3Y)(%) 17.50
ABMD's Revenue Growth (3Y)(%) is ranked higher than
92% of the 346 Companies
in the Global Medical Devices industry.

( Industry Median: 4.70 vs. ABMD: 17.50 )
ABMD' s 10-Year Revenue Growth (3Y)(%) Range
Min: -7.2   Max: 26.3
Current: 17.5

-7.2
26.3
» ABMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ABMD Guru Trades in Q1 2014

Joel Greenblatt 25,692 sh (New)
Paul Tudor Jones 11,200 sh (New)
Steven Cohen 11,972 sh (New)
PRIMECAP Management 5,751,990 sh (unchged)
Jim Simons Sold Out
» More
Q2 2014

ABMD Guru Trades in Q2 2014

Jim Simons 97,223 sh (New)
Chase Coleman 1,690,000 sh (New)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 5,726,490 sh (-0.44%)
» More
Q3 2014

ABMD Guru Trades in Q3 2014

Chase Coleman 1,690,000 sh (unchged)
Jim Simons Sold Out
PRIMECAP Management 5,664,990 sh (-1.07%)
» More
Q4 2014

ABMD Guru Trades in Q4 2014

Joel Greenblatt 22,440 sh (New)
PRIMECAP Management 5,687,590 sh (+0.40%)
Chase Coleman Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ABMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 161.60
ABMD's P/E(ttm) is ranked higher than
72% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 201.60 vs. ABMD: 161.60 )
ABMD' s 10-Year P/E(ttm) Range
Min: 36.46   Max: 946.92
Current: 161.6

36.46
946.92
Forward P/E 86.96
ABMD's Forward P/E is ranked higher than
79% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABMD: 86.96 )
N/A
PE(NRI) 159.80
ABMD's PE(NRI) is ranked higher than
73% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 140.40 vs. ABMD: 159.80 )
ABMD' s 10-Year PE(NRI) Range
Min: 36.03   Max: 820.67
Current: 159.8

36.03
820.67
P/B 14.68
ABMD's P/B is ranked lower than
52% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 4.25 vs. ABMD: 14.68 )
ABMD' s 10-Year P/B Range
Min: 1.58   Max: 14.41
Current: 14.68

1.58
14.41
P/S 13.81
ABMD's P/S is ranked lower than
51% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 3.68 vs. ABMD: 13.81 )
ABMD' s 10-Year P/S Range
Min: 2.38   Max: 13.56
Current: 13.81

2.38
13.56
PFCF 92.51
ABMD's PFCF is ranked higher than
79% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABMD: 92.51 )
ABMD' s 10-Year PFCF Range
Min: 23.56   Max: 2462
Current: 92.51

23.56
2462
POCF 85.74
ABMD's POCF is ranked higher than
73% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 78.33 vs. ABMD: 85.74 )
ABMD' s 10-Year POCF Range
Min: 21.88   Max: 463.25
Current: 85.74

21.88
463.25
EV-to-EBIT 138.95
ABMD's EV-to-EBIT is ranked higher than
71% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 73.27 vs. ABMD: 138.95 )
ABMD' s 10-Year EV-to-EBIT Range
Min: -305.5   Max: 694.7
Current: 138.95

-305.5
694.7
Current Ratio 5.11
ABMD's Current Ratio is ranked higher than
86% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.51 vs. ABMD: 5.11 )
ABMD' s 10-Year Current Ratio Range
Min: 3.18   Max: 15.95
Current: 5.11

3.18
15.95
Quick Ratio 4.62
ABMD's Quick Ratio is ranked higher than
88% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 1.89 vs. ABMD: 4.62 )
ABMD' s 10-Year Quick Ratio Range
Min: 2.56   Max: 15.43
Current: 4.62

2.56
15.43
Days Inventory 133.11
ABMD's Days Inventory is ranked higher than
76% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 166.67 vs. ABMD: 133.11 )
ABMD' s 10-Year Days Inventory Range
Min: 128.06   Max: 314.91
Current: 133.11

128.06
314.91
Days Sales Outstanding 48.58
ABMD's Days Sales Outstanding is ranked higher than
90% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 79.87 vs. ABMD: 48.58 )
ABMD' s 10-Year Days Sales Outstanding Range
Min: 48.41   Max: 160.07
Current: 48.58

48.41
160.07

Valuation & Return

vs
industry
vs
history
Price/Net Cash 42.10
ABMD's Price/Net Cash is ranked higher than
81% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABMD: 42.10 )
ABMD' s 10-Year Price/Net Cash Range
Min: 1.29   Max: 73.96
Current: 42.1

1.29
73.96
Price/Net Current Asset Value 24.85
ABMD's Price/Net Current Asset Value is ranked higher than
73% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 327.00 vs. ABMD: 24.85 )
ABMD' s 10-Year Price/Net Current Asset Value Range
Min: 1.08   Max: 22.32
Current: 24.85

1.08
22.32
Price/Tangible Book 19.97
ABMD's Price/Tangible Book is ranked higher than
53% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 7.90 vs. ABMD: 19.97 )
ABMD' s 10-Year Price/Tangible Book Range
Min: 1   Max: 16.93
Current: 19.97

1
16.93
Price/DCF (Projected) 10.05
ABMD's Price/DCF (Projected) is ranked higher than
80% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABMD: 10.05 )
ABMD' s 10-Year Price/DCF (Projected) Range
Min: 4.39   Max: 41.45
Current: 10.05

4.39
41.45
Price/Median PS Value 2.25
ABMD's Price/Median PS Value is ranked higher than
57% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. ABMD: 2.25 )
ABMD' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 4.29
Current: 2.25

0.38
4.29
Price/Graham Number 11.75
ABMD's Price/Graham Number is ranked higher than
72% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABMD: 11.75 )
ABMD' s 10-Year Price/Graham Number Range
Min: 2.97   Max: 15.85
Current: 11.75

2.97
15.85
Earnings Yield (Greenblatt) 0.70
ABMD's Earnings Yield (Greenblatt) is ranked higher than
67% of the 468 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. ABMD: 0.70 )
ABMD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 3.7
Current: 0.7

0.1
3.7

Analyst Estimate

Mar15 Mar16 Mar17 Mar18
Revenue(Mil) 226 271 336 416
EPS($) 0.52 0.81 1.22 1.75
EPS without NRI($) 0.52 0.81 1.22 1.75

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:AIO.Germany,
Abiomed Inc is a Delaware corporation incorporated on June 4, 1987. The Company is engaged in providing mechanical circulatory support devices and it offers a continuum of care in heart recovery to heart failure patients. The Company develops, manufactures and markets proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. Its products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. The Companys product portfolio includes; Impella 2.5, Impella CP, Impella RP, AB5000, Symphony, and Impella 5.0 & Impella LD. The Companys Impella 2.5 catheter is a percutaneous micro heart pump with an integrated motor and sensors for use mainly in interventional cardiology. The device is designed mainly for use by interventional cardiologists to support patients in the cath lab who may require assistance to maintain their circulation. The Impella 5.0 catheter and Impella LD are percutaneous micro heart pumps with integrated motors and sensors for use mainly in the heart surgery suite. These devices are designed to support patients who require higher levels of circulatory support as compared to the Impella 2.5. The Impella RP is a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute and to provide the flow and pressure needed to compensate for right heart failure. The Company manufactures & sells the AB5000 Circulatory Support System for the temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. The Company faces competition from Getinge (Maquet Cardiovascular), Teleflex Inc., Thoratec Corporation, HeartWare International Inc., Jarvik Heart, Terumo Heart, Inc. and CardiacAssist Inc. The Companys business is subject to extensive federal, state, local and foreign regulation.
» More Articles for NAS:ABMD

Headlines

Articles On GuruFocus.com
Impressive Numbers That Matter: Abiomed Inc (ABMD), Freescale Semiconductor Ltd (FSL), Apple Inc (AA Jan 28 2015 
Vycor Value Could be Unlocked with These Major Partnerships Dec 05 2014 
Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
BSX and ABMD Highlight Increased Insider Buying in the Medical Technology Sector May 14 2013 
Weekly CFO Sells Highlight: BDSI, LNKD, VRSK, ABMD, AGX Jul 17 2012 
ABIOMED Inc. Reports Operating Results (10-Q) Feb 04 2011 
ABIOMED Inc. Reports Operating Results (10-Q) Aug 05 2010 
ABIOMED Inc. (ABMD) COO David M Weber sells 1,389 Shares May 25 2010 
ABIOMED Inc. (ABMD) President, CEO, Chairman Michael R Minogue sells 4,491 Shares May 25 2010 
Trade Setups for May 19, 2010 May 19 2010 


More From Other Websites
Varian (VAR) Showcases Edge Radiosurgey at 2015 ChinaMed - Analyst Blog Mar 27 2015
Hanger Goes Downhill on Moody's Rating Cut, NYSE Notice - Analyst Blog Mar 27 2015
Cepheid's Xpert Ebola Gets FDA's Nod for Emergency Use - Analyst Blog Mar 27 2015
Zacks Industry Outlook Highlights: Boston Scientific, Edwards Lifesciences, Natus Medical, Hologic... Mar 27 2015
Inogen's Texas Facility Ready, Costs Likely to Scale Down - Analyst Blog Mar 26 2015
MedTech M&As Continue Regardless of Tax Scenarios - Industry Outlook Mar 26 2015
Can The Uptrend Continue for ABIOMED (ABMD)? - Tale of the Tape Mar 26 2015
Allscripts and Drexel University Extend EHR Alliance - Analyst Blog Mar 25 2015
Abiomed Attains New 52-Week High on Impella 2.5 Approval - Analyst Blog Mar 25 2015
Palo Alto Rejoicing at ABIOMED, Inc. (ABMD)’s 18% Spike Mar 25 2015
ABIOMED (ABMD) in Focus: Stock Surges 18% in Session - Tale of the Tape Mar 25 2015
ABIOMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 24 2015
Investors pump up Abiomed's stock to all-time high on new approval Mar 24 2015
Abiomed's Impella 2.5 FDA-Approved for PCI Procedures - Analyst Blog Mar 24 2015
Abiomed Stock Hits High On Heart Pump Approval Mar 24 2015
FDA Grants Premarket Approval To AbioMed Heart Pump Mar 24 2015
Early movers: Estée Lauder, Abiomed & more Mar 24 2015
Abiomed Impella 2.5 Receives FDA Approval for Elective and Urgent High Risk Percutaneous Coronary... Mar 23 2015
FDA approves Abiomed's blood pump device Mar 23 2015
Abiomed Impella 2.5 Receives FDA Approval for Elective and Urgent High Risk Percutaneous Coronary... Mar 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK